
Press Release

January 17, 2025

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Announces Organizational Realignment and Personnel Changes

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced the following organizational realignment and personnel changes, effective February 1, 2025.

I. Organizational Realignment (effective February 1, 2025)

Corporate Departments

As announced on December 17, 2024, following the establishment of RACTHERA Co., Ltd., a joint venture for regenerative medicine and cell therapy business with Sumitomo Chemical Co., Ltd. (company split (simplified absorption-type company split) and transfer of subsidiary shares), Sumitomo Pharma's organizations related to regenerative medicine and cell therapy business (Regenerative & Cellular Medicine Office, Regenerative & Cellular Medicine Kobe Center, Regenerative & Cellular Medicine Manufacturing Plant) will be reorganized and transferred to RACTHERA and S-RACMO Co., Ltd., a joint venture between Sumitomo Pharma and Sumitomo Chemical. In line with the transfer, Regenerative Medicine Office is created in Sumitomo Pharma as a department to maximize the leverages of the Sumitomo Pharma's technologies and knowledge in the field of regenerative and cellular medicine and to promote collaboration with affiliated companies.

II. Changes in Personnel (effective February 1, 2025)

Corporate Departments

Position as of February 1, 2025	Current position	Name
External Affairs; Corporate Governance; IT Management & Data Analytics Vice President, Head of External Affairs	Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant; External Affairs; Corporate Governance; IT Management & Data Analytics Vice President, Head of External Affairs Vice President, Head of Regenerative & Cellular Medicine Office	Tomokazu Nagano

Representative Director, President and CEO, RACTHERA Co., Ltd. Corporate Officer, Regenerative Medicine Office	Vice President, Head of Regenerative & Cellular Medicine Kobe Center	Atsushi Ikeda
Representative Director, President and CEO, S-RACMO Co., Ltd. Corporate Officer, Regenerative Medicine Collaboration	Representative Director, President and CEO, S-RACMO Co., Ltd.	Atsushi Tsuchida
Senior officer, Regenerative & Cellular Medicine Business RACTHERA Co., Ltd.	Senior officer, Regenerative & Cellular Medicine Business	Makoto Inoue
Senior Medical Officer, Ophthalmology RACTHERA Co., Ltd. Regenerative Medicine Office	Senior Medical Officer, Ophthalmology	Koichiro Manabe
Vice President, RACTHERA Co., Ltd. Vice President, Head of Regenerative Medicine Office	Officer, Regenerative & Cellular Medicine Office	Kenji Yoshida
Vice President, RACTHERA Co., Ltd.	Senior Director, Business Planning Group, Regenerative & Cellular Medicine Office	Takashi Yoshikawa
Vice President, S-RACMO Co., Ltd. Vice President, RACTHERA Co., Ltd.	Vice President, Head of Regenerative & Cellular Medicine Manufacturing Plant	Hidetaka Ohara
Vice President, RACTHERA Co., Ltd.	Senior Director, Tissue and organ regeneration Group, Stem cell engineering Group, Regenerative & Cellular Medicine Kobe Center	Ryo Yamaguchi

*The following press releases were issued on December 17, 2024 in connection with this matter.
Sumitomo Chemical and Sumitomo Pharma to Establish Regenerative Medicine and Cell Therapy Joint Venture <https://www.sumitomo-pharma.com/news/20241217-2.html>

Notice Regarding Company Split (Simplified Absorption-type Company Split) of the Regenerative Medicine and Cell Therapy Business and Transfer of Subsidiary Shares
<https://www.sumitomo-pharma.com/news/20241217-1.html>

Contact:

Corporate Communications, Global Finance
Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp